RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
+10.96%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$783M
AUM Growth
+$86.9M
(+12%)
Cap. Flow
+$41.9M
Cap. Flow
% of AUM
5.35%
Top 10 Holdings %
Top 10 Hldgs %
30.88%
Holding
120
New
12
Increased
45
Reduced
27
Closed
26
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$14.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$12.9M |
| 3 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.6M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$10.1M |
| 5 |
Glaukos
GKOS
|
$9.98M |
Top Sells
| 1 |
Pfizer
PFE
|
$15M |
| 2 |
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
|
$13.8M |
| 3 |
Zimmer Biomet
ZBH
|
$11.6M |
| 4 |
NovoCure
NVCR
|
$10.9M |
| 5 |
Biogen
BIIB
|
$8.3M |
Sector Composition
| 1 | Healthcare | 89.3% |
| 2 | Financials | 1.39% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.13% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIVV
76
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $2M | 0.25% |
35,000
+4,000
| +13% | +$228K |
|
|
RARX
77
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.75M | 0.22% |
+119,697
| New | +$1.75M |
|
78
STAAR Surgical
STAA
$1.36B
| $1.12M | 0.14% |
90,000
+20,050
| +29% | +$250K |
|
|
LUMO
79
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.02M | 0.13% |
+11,111
| New | +$1.02M |
|
80
Agios Pharmaceuticals
AGIO
$2.05B
| $1M | 0.13% |
+15,000
| New | +$1M |
|
|
RGLS
81
DELISTED
Regulus Therapeutics
RGLS
| $725K | 0.09% |
4,833
-114
| -2% | -$17.1K |
|
82
Adverum Biotechnologies
ADVM
$67.4M
| $562K | 0.07% |
15,401
| – | – |
|
83
JPMorgan Chase
JPM
$834B
| $539K | 0.07% |
5,641
+804
| +17% | +$76.8K |
|
84
Halliburton
HAL
$19B
| $513K | 0.07% |
11,144
+3,426
| +44% | +$158K |
|
85
Wells Fargo
WFC
$262B
| $477K | 0.06% |
8,653
+1,348
| +18% | +$74.3K |
|
86
Exxon Mobil
XOM
$480B
| $467K | 0.06% |
5,696
+873
| +18% | +$71.6K |
|
|
87
Pfizer
PFE
$140B
| $372K | 0.05% |
10,985
-442,680
| -98% | -$15M |
|
88
Microsoft
MSFT
$3.77T
| $357K | 0.05% |
4,793
| – | – |
|
89
Ford
F
$46.4B
| $340K | 0.04% |
28,404
| – | – |
|
90
AB InBev
BUD
$116B
| $335K | 0.04% |
2,806
| – | – |
|
91
Gen Digital
GEN
$18.2B
| $307K | 0.04% |
+9,359
| New | +$307K |
|
92
Qualcomm
QCOM
$170B
| $278K | 0.04% |
5,368
| – | – |
|
93
IBM
IBM
$231B
| $256K | 0.03% |
1,847
| – | – |
|
94
Halozyme
HALO
$8.69B
| – | – |
-120,000
| Closed | -$1.54M |
|
95
Acadia Pharmaceuticals
ACAD
$4.31B
| – | – |
-30,000
| Closed | -$837K |
|
96
Amgen
AMGN
$152B
| – | – |
-35,000
| Closed | -$6.03M |
|
97
Astria Therapeutics
ATXS
$381M
| – | – |
-5,179
| Closed | -$441K |
|
98
Cardinal Health
CAH
$35.7B
| – | – |
-55,000
| Closed | -$4.29M |
|
99
DaVita
DVA
$9.74B
| – | – |
-55,000
| Closed | -$3.56M |
|
100
Hologic
HOLX
$14.6B
| – | – |
-70,000
| Closed | -$3.18M |
|